课题基金 / 基金详情

BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE

BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
BAA-HLA 数据的开发应用
批准号:
6360186
负责人:
lawrence stern
金额:
$32.37万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-05-01 至 2004-04-30

项目摘要

项目成果

lawrence stern的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Effective immune responses require the development of T lymphocytes specific for antigens presented by self major histocompatibility complex (MHC) class I and class II molecules. Many basic and clinical studies require the detection and enumeration of antigen- specific T lymphocytes, but until recently their detection was inaccurate and cumbersome, requiring extensive tissue culture procedures. New reagents have been developed, comprised of four identical MHC molecules, each presenting a defined antigenic peptide. The reagent is fluorescently labeled to enable the direct detection of T cells that bind the reagent by their specific antigen receptor molecules. Previous research has established the approach for class I MHC molecules that bind to cytotoxic T cells, but reagents based upon class II MHC molecules, which would detect helper T lymphocytes, are less well-developed. This contract will focus on the development and utilization of class II MHC-peptide tetramers to detect and study antigen specific T cells. Studies will include: a) testing various forms of class II MHC-peptide complexes to optimize the reagents, b) demonstrate the reagents~ ability to detect human T cells in clinical samples and c) combine detection with functional T cell assays to increase the information obtained. Because helper T cells are central to virtually all immune responses, this technology is applicable to studies in many areas, including basic immune mechanisms, infectious diseases, vaccination, autoimmunity, transplant rejection, and tumor therapy.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
HIV DERIVED PEPTIDES AS CLASS II MHC ANTIGENS
BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
HIV DERIVED PEPTIDES AS CLASS II MHC ANTIGENS
BAA APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
海外基金